CClinicalTrials.gg
Active, not recruitingNCT05934851Updated Jul 13, 2026

A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

An interventional study of Frozen-Section Directed Excision and Wide Local Excision in Vulvar Neoplasm and Dysplasia Vulvar, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.

Read the detailed description

This is a randomized, single-blinded study. The target population is adults ≥ 18 years of age with histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures. One group of subjects will be assigned to the Frozen-Section Directed Excision surgery arm and will undergo this procedure. The other group of subjects will be assigned to the Wide Local Excision (standard of care) arm and will undergo this procedure. The randomization will be 1:1, meaning for every subject who gets assigned to the Frozen-Section Directed Excision surgery arm, one will also be assigned to the Wide Local Excision arm. There is a 50% chance of getting randomized to either the Frozen-Section Directed Excision procedure or Wide Local Excision. Information regarding the surgery procedure, the amount of time the surgery procedure takes, and total amount of pain medication required during surgery and while in the surgery recovery area will be collected. The study team will also look at recurrence rates (return of the cancer) in six months, if any other therapies are required, and subject satisfaction related to the surgery, recovery, and sexual function by using questionnaires before and after the procedure.

02

Conditions studied

  • Vulvar Neoplasm
  • Dysplasia Vulvar

Browse trials for

03

In context

Vulvar Neoplasms

210 studies on the registry are indexed under Vulvar Neoplasms; 71 are open to participants now.

This study's planned enrollment of 112 is above the median of 55 across 151 interventional studies indexed under Vulvar Neoplasms.

Browse Vulvar Neoplasms studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent and HIPAA authorization for release of personal health information.
  2. Age ≥ 18 years at the time of consent
  3. Histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures
  4. Surgery is expected to occur within 90 days from randomization
  5. Ability to read and understand the English and/or Spanish language
  6. As determined by the enrolling physician, ability and willingness of the subject to comply with study procedures for the entire length of the study
  7. No known pregnancy

Exclusion criteria

Exclusion Criteria:

  1. Excision is not possible due to anatomy (proximity to urethra/clitoris)
  2. Known immunodeficiency syndrome
  3. Immunosuppressant medications taken within the last 30 days (HIV, organ transplant recipient, chronic steroid use/immunosuppressant)
  4. History of pelvic region radiation therapy
  5. Active anticancer treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Frozen-Section Directed Excision Vulvectomy

    The surgeon(s) will identify the lesion and make a 1 mm excision around the lesion site.

    Procedure: Frozen-Section Directed Excision

  • Active comparator
    Wide Local Excision Vulvectomy

    The surgeon(s) will visually identify the abnormal lesion. A Wide Local Excision with 5 mm margins will be made through the dermis per standard of care.

    Procedure: Wide Local Excision

Interventions

  • ProcedureFrozen-Section Directed Excision

    Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.

    Also known as: FSDE

  • ProcedureWide Local Excision

    Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS

06

What researchers measure

Primary outcomes

  1. Rates of positive margins for VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS

    Comparison of rates of positive margins for VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS in subjects who undergo standard of care Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: At the time of the resection

Secondary outcomes

  1. Recurrence rates at 6 months

    Comparison of recurrence rates in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: 6 months post resection surgery

  2. Surgical time

    Comparison of surgical time in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: At the time of the resection

  3. Recovery room time

    Comparison of recovery room time in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: At the time of the resection and recovery

  4. Narcotic dose required (total during surgery and in recovery)

    Comparison of narcotic dose required in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: At the time of the resection and recovery

  5. Blood loss

    Comparison of blood loss in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: At the time of the resection

  6. Primary wound closure rates

    Comparison of primary wound closure rates in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: 2-week post resection surgery

  7. Post-operative quality of life as determined by the SSQ-8

    Comparison of post-operative quality of life as determined by the SSQ-8 in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: 2-weeks and 6 months after resection surgery

  8. Sexual function as determined by the FSFI

    Comparison of sexual function as determined by the FSFI in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: Screening and 6 months after resection surgery

  9. Wound bed size after surgery

    Comparison of wound bed size after surgery in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Time frame: End of resection surgery

07

Study locations

1 site
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
08

References and documents

Study documents

  • Informed consent form · Aug 26, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05934851
Lead sponsor
Wake Forest University Health Sciences
Collaborators
Atrium Health Levine Cancer Institute
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Nov 7, 2023
Primary completion
Mar 24, 2026
Completion
Oct 24, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Robert W Naumann, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion